ArticleBMC geriatrics2026
Efficacy and safety of immunotherapy in elderly patients with advanced non-small cell lung cancer: a real-world study stratified by age.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the efficacy and safety of immunotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC), stratified by age.
methodsA retrospective analysis included elderly patients (≥ 65 years) diagnosed with stage III–IV NSCLC who received immunotherapy at the PLA General Hospital between January 2016 and October 2024. Participants were stratified into two age groups: <75 years and ≥ 75 years. Propensity score matching (PSM) was applied to balance baseline characteristics, including age, Eastern Cooperative Oncology Group performance status (ECOG PS) score, and treatment line. Primary endpoints were objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and drug safety.
resultsAmong 535 enrolled patients, the median age was 70 years. The ORR was 54.40% in the group aged < 75 years and 41.75% in the group aged ≥ 75 years. Median overall survival (mOS) was 29.23 months for the < 75 years group and 27.93 months for the ≥ 75 years group. No significant differences were observed between groups in OS (HR = 1.274, P = 0.068) or PFS (HR = 0.907, P = 0.421). The overall incidence of adverse events (AEs) was 90.28%, with no significant differences in AE rates across age groups.
conclusionImmunotherapy demonstrated feasibility and efficacy in elderly patients with advanced NSCLC. Age did not significantly affect survival outcomes between subgroups (< 75 vs. ≥75 years), and safety was manageable. These findings suggest that the 75-year threshold alone should not preclude treatment; instead, clinical decisions should be guided by a comprehensive geriatric assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.